SCHEDULE 13G: Eminence Capital Reduces Stake in Cresco Labs to 4.2% as of Year-End 2023
Beneficial Ownership Report
Eminence Capital, LP and Ricky C. Sandler have filed a Schedule 13G indicating a decrease in their beneficial ownership of Cresco Labs Inc.'s Subordinate Voting Shares from 6.3% at the end of 2022 to 4.2% by the end of 2023.
Summary
- Eminence Capital, LP and Ricky C. Sandler, collectively referred to as the Reporting Persons, filed a Schedule 13G concerning their beneficial ownership in Cresco Labs Inc.
- As of December 31, 2022, the Reporting Persons beneficially owned 17,753,792 Subordinate Voting Shares of Cresco Labs Inc., representing 6.3% of the outstanding class.
- This percentage was calculated based on 281,147,586 Subordinate Voting Shares outstanding as of December 31, 2022.
- A footnote indicates that as of December 31, 2023, the Reporting Persons may have been deemed to beneficially own 13,338,389 Subordinate Voting Shares, representing 4.2% of the outstanding shares.
- The 2023 percentage is based on 320,757,119 Subordinate Voting Shares outstanding as of December 31, 2023.
- Eminence Capital, LP acts as the management company or investment adviser for various investment funds and a separately managed account holding these shares.
- Ricky C. Sandler is the Chief Executive Officer of Eminence Capital and is deemed to have shared voting and dispositive power over these shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual report of beneficial ownership, indicating a decrease in stake. It does not contain forward-looking statements or operational performance details that would significantly sway sentiment beyond neutral.
Negatives
- The beneficial ownership stake of Eminence Capital and Ricky C. Sandler in Cresco Labs Inc. decreased from 6.3% as of December 31, 2022, to 4.2% as of December 31, 2023.
Future Outlook
NA
Industry Context
This filing reflects a change in a significant institutional investor's stake in Cresco Labs Inc., a company operating in the cannabis industry. Such changes can be indicative of an investor's evolving view on the company's prospects or broader industry trends, though this specific filing is passive and does not state an intent to influence control.
Stakeholder Impact
- Shareholders: The reduction in a significant institutional stake could be interpreted by other shareholders as a signal regarding the investor's confidence or portfolio rebalancing, potentially influencing their own investment decisions.
Key Dates
| Date | Description |
|---|---|
| 12/31/2022 | Date of event which required the filing of this statement, reflecting 6.3% beneficial ownership. |
| 03/22/2023 | Date Cresco Labs Inc.'s Annual Report on Form 40-F for fiscal year ended December 31, 2022, was filed, reporting 281,147,586 Subordinate Voting Shares outstanding. |
| 12/31/2023 | Date reflecting a reduced beneficial ownership of 4.2%. |
| 03/18/2024 | Date Cresco Labs Inc.'s Annual Report on Form 40-F for fiscal year ended December 31, 2023, was filed, reporting 320,757,119 Subordinate Voting Shares outstanding. |
| 02/14/2025 | Date the Schedule 13G filing was signed by Eminence Capital, LP and Ricky C. Sandler. |
Keywords
Cresco Labs Inc., Eminence Capital, Ricky C. Sandler, Schedule 13G, Beneficial Ownership, Subordinate Voting Shares, Institutional Investor, SEC Filing, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.